FORM	4
------	---

(Print or Type Responses)

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> Chow Gregory K.		2. Issuer Name and Aptose Bioscienc		-			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) ( C/O APTOSE BIOSCIENCES INC., 25 CONSUMERS ROAD, SUITE 1105		. Date of Earliest Tra 1/04/2021	ansaction (N	Ionth	/Day/Year	:)	X_Officer (give title below) Oth Executive VP & C	er (specify below FO	w)		
(Street) TORONTO, A6 M2J 4R3	4	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
(Instr. 3) Da	Date Month/Day/Year)	Execution Date, if	3. Transacti Code (Instr. 8)	ion	4. Securi (A) or Di (Instr. 3,	sposed of 4 and 5)	f (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Direct (D) or Indirect	Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price		(I) (Instr. 4)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	tion )	5. Number of Derivative		6. Date Exer Expiration I (Month/Day	Date	1		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form of Derivative Security: Direct (D) or Indirect (I)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Employee Stock Option (Right to Buy)	\$ 4.37	01/04/2021		A		343,000		(1)	01/04/2031	Common Shares	343,000	\$ 0	343,000	D	

## **Reporting Owners**

		Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Chow Gregory K. C/O APTOSE BIOSCIENCES INC. 251 CONSUMERS ROAD, SUITE 11 TORONTO, A6 M2J 4R3	05		Executive VP & CFO					

### Signatures

/s/ Janet Clennett as attorney-in-fact for Gregory K. Chow 01/06/2021 <u>\*\*Signature of Reporting Person</u>
Date

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The options were granted on January 4, 2021. One-half of the options vest on January 4, 2022. The remaining one-half of the options vest as follows: 1/3 on January 4, 2023; 1/3 on January 4, 2023; 1/3 on January 4, 2024; and 1/3 on January 4, 2025.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.